News

Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...
1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...
BMO Maintains Outperform Rating on Eli Lilly (LLY), Sets $900 PT
BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...
PharmExec4d
Roundup: Pharma Giants Expand Strategic Pipelines Through Targeted M&A and Partnerships
Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...
BMO Capital Markets Reiterates ‘Buy’ Rating on Eli Lilly Stock (LLY)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
PharmTech2d
Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More
Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.
Yahoo Finance5d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other ...